Harmane-d2
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Harmane-d2
Description:
Harmane-d2 is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM) . Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively) [1][2][3][4].UNSPSC:
12352005Target:
Adrenergic Receptor; Imidazoline Receptor; Isotope-Labeled Compounds; Monoamine OxidaseType:
Isotope-Labeled CompoundsRelated Pathways:
GPCR/G Protein; Neuronal Signaling; OthersApplications:
Cancer-programmed cell deathField of Research:
Cancer; Neurological DiseaseSolubility:
10 mM in DMSOSmiles:
CC1=NC ([2H]) =C ([2H]) C2=C1NC3=C2C=CC=C3Molecular Formula:
C12H8D2N2Molecular Weight:
184.23References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Louis ED, et, al. Blood harmane concentrations and dietary protein consumption in essential tremor. Neurology. 2005 Aug 9;65 (3) :391-6.|[3]Musgrave IF, et, al. Harmane produces hypotension following microinjection into the RVLM: possible role of I (1) -imidazoline receptors. Br J Pharmacol. 2000 Mar;129 (6) :1057-9.|[4]Glover V, et, al. β-Carbolines as selective monoamine oxidase inhibitors:In vivo implications|[5]Umezawa K, et, al. Comutagenic effect of norharman and harman with 2-acetylaminofluorene derivatives. Proc Natl Acad Sci U S A. 1978 Feb;75 (2) :928-30.Shipping Conditions:
Room temperatureScientific Category:
Isotope-Labeled CompoundsClinical Information:
No Development Reported
